Xie Yubo, Yin Yongshuo, Li Lei, Ma Yulin, Xiao Qiang
Department of Surgery, The First Affiliated Hospital, Guangxi Medical University, Guangxi 530021, PR China.
Oncol Rep. 2009 May;21(5):1345-53. doi: 10.3892/or_00000360.
Gastric cancer is the third most common cancer in China. The sustained overexpression of E2F-1 is a characteristic feature of gastric cancer. RNA interference (RNAi), which has been proven to be a powerful tool for suppressing gene expression, may provide a promising way forward in gastric cancer therapy. In this study, we constructed the recombinant Psilencer 4.1- E2F-1 siRNA plasmids and transfected them into gastric cancer MGC-803 cells in vitro. Our data demonstrated that E2F-1 siRNA led to inhibition of endogenous E2F-1 mRNA and protein expression as determined by real-time quantitative RT-PCR and Western blotting. Furthermore, simultaneous silencing of E2F-1 resulted in a reduction of tumor cell proliferation activity and a higher percentage of apoptotic cells. The inhibition of migration and invasion potential of tumor cells was investigated in vitro. In summary, siRNA targeting of E2F-1 can effectively inhibit gastric cancer progression and may be used as a potent therapy.
胃癌是中国第三大常见癌症。E2F-1的持续过表达是胃癌的一个特征。RNA干扰（RNAi）已被证明是抑制基因表达的有力工具，可能为胃癌治疗提供一条有前景的途径。在本研究中，我们构建了重组Psilencer 4.1-E2F-1 siRNA质粒，并在体外将其转染到胃癌MGC-803细胞中。我们的数据表明，通过实时定量RT-PCR和蛋白质免疫印迹法测定，E2F-1 siRNA导致内源性E2F-1 mRNA和蛋白质表达受到抑制。此外，同时沉默E2F-1导致肿瘤细胞增殖活性降低和凋亡细胞百分比升高。在体外研究了对肿瘤细胞迁移和侵袭潜能的抑制作用。总之，靶向E2F-1的siRNA可有效抑制胃癌进展，可能用作一种有效的治疗方法。
